MEI Pharma Initiates Clinical Study Of Mitochondrial Inhibitor Drug Candidate ME-344 In Small Cell Lung And Ovarian Cancers

[PR Newswire] – SAN DIEGO, May 5, 2014 /PRNewswire/ — MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patient has been dosed in a Phase Ib clinical study of i more

View todays social media effects on MEIP

View the latest stocks trending across Twitter. Click to view dashboard

See who MEI is hiring next, click here to view